Dr. John P. Crow This is Me

Education

 View all 15 references Web References

1. 1. Pharmacyclics Announces Motexafin Gadolinium Improved Survival in Animal Models of ALS

   www.prnewswire.com/cgi-bin/sto - [Cached]

   Published on: 12/8/2005   Last Visited: 12/8/2005

   The data was presented by John P. Crow, Ph.D., Professor of Pharmacology and Toxicology, University of Arkansas for Medical Science, at the 16th Annual International Symposium on ALS/MND (Motor Neuron Disease) held this week in Dublin, Ireland. The study entitled, "Onset Administration of MGd Extends Survival in G93A Mice," demonstrated that mice receiving MGd after disease onset showed a 2.5 fold increase in survival and improved neurologic function versus control. Researchers at the University of Arkansas for Medical Science, in collaboration with Pharmacyclics, measured the neuroprotective effect of MGd in a mouse model of ALS and found it increased expression of several proteins in the spinal cord known to be neuroprotective. They concluded that these findings suggest that MGd could be a useful therapeutic agent in ALS and other neurodegenerative diseases by inducing neuroprotective oxidative-stress- related proteins. A study published in the May 2005 issue of Cancer Research, the journal of the American Association for Cancer Research (AACR), reported on the effect of MGd in cancer cells and indicated that the drug induced the expression of oxidative-stress-related genes. The publication proposed that various tissues in the body would respond differently to MGd-induced oxidative stress. "Together, these studies suggest that MGd may have similar effects in cancer cells and neuronal tissue," said Dr. Crow.

2. 2. ir.pharmacyclics.com

   ir.pharmacyclics.com/releasede - [Cached]

   Published on: 12/8/2005   Last Visited: 8/3/2007

   The data was presented by John P. Crow, Ph.D., Professor of Pharmacology and Toxicology, University of Arkansas for Medical Science, at the 16th Annual International Symposium on ALS/MND (Motor Neuron Disease) held this week in Dublin, Ireland.
   ...
   "Together, these studies suggest that MGd may have similar effects in cancer cells and neuronal tissue," said Dr. Crow.

3. 3. Crow presents at AA Neurology News Release

   www.aeoluspharma.com/press/200 - [Cached]

   Published on: 4/26/2004   Last Visited: 9/9/2005

   John P. Crow, Ph.D., Professor of Pharmacology and Toxicology at the University of Arkansas College of Medicine, who conducted the experiments, was invited to present the results Sunday, April 25 in San Francisco at the 56th Annual Meeting of the American Academy of Neurology.
   
   Dr. Crow summarized four separate studies in a transgenic mouse model of ALS, conducted in two academic medical centers over an 18-month period.